Prostaglandin E-major urinary metabolite as a noninvasive surrogate marker for infantile necrotizing enterocolitis
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Oct 2018 · 1 min read
In brief
In brief
Study validates urinary prostaglandin E2 metabolite (PGE-MUM) as a noninvasive biomarker for necrotizing enterocolitis in infants, demonstrating 92.3% sensitivity and 81.5% specificity. PGE-MUM levels were significantly elevated in NEC patients compared to healthy controls, offering potential for earlier diagnosis than traditional Bell staging criteria.
Written by the GCMD Library team from the article.
Background
Early definitive diagnosis of necrotizing enterocolitis (NEC) based on Bell's staging criteria is difficult because there are few observable changes on abdominal imaging and blood chemistry tests at the onset of the disease.
Purpose
To investigate whether prostaglandin E-2 major urinary metabolite (PGE-MUM) can be a useful surrogate marker reflecting the disease state and severity of NEC in infants.
Methods
Infants were enrolled in this study between January 2014 and December 2016. NEC diagnosis was based on Bell's staging criteria > Stage II or necrotic bowel observed at surgery. After diagnosis, PGE-MUM level was measured and compared with that of the other disease and healthy infant groups.
Results
Median PGE-MUM value was highest in the NEC group (576 [65–3672] μg/g•Cre/BSA × 1000), followed by the other disease group (94 [57–296] μg/g•Cre/BSA × 1000) and the healthy infant group (19 [10–44] μg/g•Cre/BSA × 1000) (sensitivity: 92.3%, specificity: 81.5%, accuracy: 85.0%; p